Klaria Pharma Holding AB (FRA:6FN) E10: €-0.05 (As of Mar. 2026)


FRA:6FN Klaria Pharma Holding AB FRA:6FN
28 GF Score
Price €0.06
GF Value €0.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB E10?

Klaria Pharma Holding AB FRA:6FN -8.28% 28 E10 is €-0.05 as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 28/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Klaria Pharma Holding AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.004. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), Klaria Pharma Holding AB's current stock price is €0.0598. Klaria Pharma Holding AB's E10 for the quarter that ended in Mar. 2026 was €-0.05. Klaria Pharma Holding AB's Shiller PE Ratio of today is .


Klaria Pharma Holding AB  (FRA:6FN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Klaria Pharma Holding AB E10 Related Terms


Klaria Pharma Holding AB E10 Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB E10 Chart

Klaria Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.06 -0.07

Klaria Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.05 -0.06 -0.07 -0.05

FRA:6FN vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klaria Pharma Holding AB Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Klaria Pharma Holding AB's Shiller PE Ratio falls into.


FRA:6FN
28GF Score
Klaria Pharma Holding AB FRA:6FN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klaria Pharma Holding AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Klaria Pharma Holding AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.004/107.1957*107.1957
=-0.004

Current CPI (Mar. 2026) = 107.1957.

Klaria Pharma Holding AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.015 100.088 -0.016
201609 -0.011 99.604 -0.012
201612 -0.010 99.380 -0.011
201703 -0.010 100.040 -0.011
201706 -0.010 100.285 -0.011
201709 -0.004 100.254 -0.004
201712 -0.041 100.213 -0.044
201803 -0.018 100.836 -0.019
201806 -0.028 101.435 -0.030
201809 -0.018 101.246 -0.019
201812 -0.024 100.906 -0.025
201903 -0.006 101.571 -0.006
201906 -0.022 102.044 -0.023
201909 -0.020 101.396 -0.021
201912 -0.014 101.063 -0.015
202003 -0.027 101.048 -0.029
202006 -0.021 100.743 -0.022
202009 -0.025 100.585 -0.027
202012 -0.032 100.241 -0.034
202103 0.029 100.800 0.031
202106 -0.028 101.352 -0.030
202109 -0.026 101.533 -0.027
202112 -0.067 101.776 -0.071
202203 -0.034 103.205 -0.035
202206 -0.022 104.783 -0.023
202209 -0.024 104.835 -0.025
202212 -0.020 104.666 -0.020
202303 -0.005 106.245 -0.005
202306 -0.008 106.576 -0.008
202309 -0.008 106.570 -0.008
202312 -0.008 106.461 -0.008
202403 -0.009 107.355 -0.009
202406 -0.010 107.991 -0.010
202409 -0.005 107.468 -0.005
202412 -0.010 107.128 -0.010
202503 -0.001 107.722 -0.001
202506 -0.013 108.075 -0.013
202509 -0.004 107.709 -0.004
202512 -0.003 107.196 -0.003
202603 -0.004 107.196 -0.004

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.05 mean?
Klaria Pharma Holding AB (FRA:6FN) has a E10 of €-0.05 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Klaria Pharma Holding AB and its competitors.
Is Klaria Pharma Holding AB's E10 too high?
Klaria Pharma Holding AB's current E10 is €-0.05. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's E10 compare to ZTS and UTHR?
Klaria Pharma Holding AB's E10 of €-0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current E10 is €-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 99.3% above its estimated fair value. The current E10 is €-0.05. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current E10 is €-0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 99.3% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • E10: €-0.05
  • GF Value™: €0.03 vs. price of €0.06 (99.3% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score

Get the complete analysis for FRA:6FN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.03
GF Value